but some novartis pharma sales people told doctors they'd deliver the data in person. hospital officials say the employees handed in morning half of the 255 responses. the leader of the study says he will suspend the research. the professor at the university of tokyo hospital says he will hear from doctors and decide whether the results are reliable. experts say the incident raises questions. >> translator: it's possible that sales staff could manipulate data to make it look good for the company. in this sense, it is very dangerous. >> novartis pharma is already under scrutiny over another of its drugs. doctors used deovan to treat high blood pressure. japanese health ministry officials say a novartis pharma employee was involved in research at several universities and they accused the firm of running ads based on manipulated data that exaggerate the drug's effects. they failed a criminal complaint against the company last week. novartis pharma representatives said in november they would not involve sales staff in clinical studies. >>> nuclear regulators have begun eva

novartis pharma is already under scrutiny over another of its products. doctors use dio and to treat high blood pressure japanese health ministry officials say. novartis pharma employee was involved in research at several universities into how dials and crew to help with other elements they accuse the firm of running ads based on manipulated data that exact rate that drives the facts they filed a criminal complaint against the company last week of artists farmer representatives said in november they would not involve sales staff in clinical studies. nuclear regulators have big on evaluating safety measures and spent nuclear fuel reprocessing plant in northern japan. the plant's operator japan nuclear fuel ltd applied for the check earlier this month nuclear regulation authority for an rta officials will investigate whether the plant in no special village comes form the new stringent safety guidelines adopted in december. an official from japan nuclear fuel says it has raised its estimate of the scale of earthquakes that could hit the plant the company pla

the market is less focused on pes in the pharma segment. that said, if you're looking for value and you're not quite as focus and growth but looking for value there's probably more opportunity over in the pharma segment right now. fundamentals in pharma continue to improve. i like merck. i think they're on a fourth inning of a recovery at that company. >> josh brown has something for you as well. >> i'm curious. what do you think pfizer is going? this seems to be a perennial also ran, saw huge rallies in bristol-myers and in merck which you just mentioned. in pfizer, returning cash to shareholders. maybe separating units out. the stock doesn't seem to keep pace with peers. what do you think is going on there and what could change that? >> so i think -- pfizer moved quickly. so it went -- when pfizer brought in a new ceo who has been a fantastic ceo. they brought him in late 2010. he moved quickly and restructured that company and returned extra cash to shareholders and cut costs at the company, thus increasing earnings. this stock out perfo

does big pharma impact the doctors in their decision to not offer alternatives to the pill here? >> i think that there is evidence that if you have interactions with pharmaceutical companies, it does impact -- and there's actually pretty good studies based -- that have looked at physician prescribing patterns and interactions with big pharma. i think one of the luxuries i have is i'm in academic medicine, and we have a policy that we don't interact with pharmaceutical companies. so i hope that gives me a better perspective. and i think a lot of these doctors aren't having these conversations with their patients because i have countless patients who come to me and said they have never heard of iud's. so i think there is some impact of that. we know there's an impact of that. and it makes it challenging, you know, to -- to have a completely unbiased view even though we as doctors like to think we have an unbiased view, there has been evidence that shows that they do impact us in some ways. so i think it's important for us to go out and educate our providers too. there is no one siz

does big pharma impact the doctors in their decision to not offer alternatives to the pill here?i think that there is evidence that if you have interactions with pharmaceutical companies, it does impact -- and there's actually pretty good studies based -- that have looked at physician prescribing patterns and interactions with big pharma. i think one of the luxuries i have is i'm in academic medicine, and we have a policy that we don't interact with pharmaceutical companies. so i hope that gives me a better perspective. and i think a lot of these doctors aren't having these conversations with their patients because i have countless patients who come to me and said they have never heard of iud's. so i think there is some impact of that. we know there's an impact of that. and it makes it challenging, you know, to -- to have a completely unbiased view even though we as doctors like to think we have an unbiased view, there has been evidence that shows that they do impact us in some ways. so i think it's important for us to go out and educate our providers too. there is no one size fi

they're supposed to be policing big pharma on our behalf.ou think that the fda is doing enough for consumers? >> no, it's not doing enough for consumers, especially since it was created for the consumer. in terms of fda regulation, they have been given more authority by a congress to impose label changes when safety information becomes available after a drug is brought on to the market. previously, it was a voluntary action on the part of a drug company to update its label. but with nuvaring, since 2007, congress gave the fda the authority to unilaterally impose a label change and they have failed to do so despite the evidence that has emerged about the risk of blood clots that is greater, of course, as i mentioned before, when compared to other hormonal contraceptives. in addition to that, they often convene advisory committees to assess safety when it comes the voting on label changes. many times, it's been found that those so called independent advisers have direct financial ties to drug companies. again, it's a question of conflicts of i

the problem is we are seeing more m & a in pharma.lth systems run by the former president of valiant looking at these deals, one of many players out there. so the more companies looking the more they have to pay for deals. what's my view? i don't know. i'm a lot more sanguine about roll-ups in general than herb is. look at hain celestial or vf corp. they have grown for years with numerous smart acquisitions. you can see there are cases where the strategy works. i like both those stocks. vfc has strong organic growth where valiant has shrinkage. they are more than valiant. hain could be swallowed up by general mills while vf corp. is worth $25 billion. as your business becomes too big growing via acquisition is hard. here's my bottom line. when herb greenberg throws a red flag, we never want to go against him. his track record is too good. that's why i'm telling you to ring the register on some of the valiant and stay away from the stock if you don't. i'm telling you it's just not worth the risk, as i have followed herb's work for 20 y

>> it would arguably say this is an opportunity that large pharma and biotech would be very interested in having. so it makes a lot of sense that this would be a take-out candidate for sure. so we have to wait and see. as you noted, there's only 25 employees. so obviously going to have to scale up and really ante up to market a drug of this size. but realistically, this is something that probably ends up better in the hands of large pharma. >> jonathan eckert, biotechnology analyst at citi, thank you. >>> tiffany raptor's holiday report in a blue backs but it doesn't impress investors. that's where we begin tonight's market focus. sales rose 4% from november through december. driven by demand in the u.s. and asia. but the company kept its full year earnings forecast unchanged and many view that as disappointing. shares fell nearly 2% to $90.36. shares of humana on the down side. the health insurer said it now expects unhealthier and costlier customers than it had first predicted. the company expects higher medical bills because of the government's decision to let some people keep their

i mean let's talk about how deep these pockets go how big is the big pharma lobbying machine in washington. it's most people feel like it's the number one lobby right now and when you look at the relationship between pharmaceutical companies in the f.d.a. it's ludicrous relationship the f.d.a. is supposedly overseeing pharmaceutical companies to put out safe drugs but yet the same time they get around thirty thirty five percent of their budget from these same pharmaceutical companies that have to pay fees to the f.d.a. to get their drugs put on the market and often people think i'm constantly bashing the f.d.a. the pharmaceutical companies there are good people. all that work in both of these agencies and in pharmaceutical companies however i think that the interests of the people at the top of these pyramids i'm not always genuine and we've seen time and time again where medications are are put on the market that should never gotten on the market information studies are suppressed and then it isn't until the drug kills or maims enough people that you see the pharma super see the f.d.a. ri

still to come: the side effects of owning a high flying pharma stock in chart talk... plus...a game of "which stock would you rather" in traders unplugged and... what prompted the labor market to hit the brakes on layoffs... that's coming up with bill moller! th a deadly disease. i was one of them. i'm a nurse and i knew how damaging the disease was to my life. nothing i tried seemed to work. my brother died. from complications of the exact same preventable disease and i knew i had to do something to get healthy. my disease was obesity and after consulting with my doctor, i received the effective treatment i needed. obesity is a second leading cause of preventable death in the united states. but it's a treatable disease, and there's effective treatment options available. now is time to get help. please join the obesity action coalition and acknowledge obesity as a disease for acceptance, for access to all effective treatments, including diet and exercise, pharmacotherapy and weight-loss surgery for obese adults with at least one obesity related comorbid condition. visi

studies are suppressed and then it isn't until the drug kills one maims no people that you see the pharma super see the f.d.a. riding in on a white horse to take a drug off the market that should have never been on the market in the first place it's ludicrous. patents for life saving medication etc i just wanted to follow up because you're a doctor i mean i think a lot of people who visit a doctor proceed an ad on t.v. about restless leg syndrome or whatever else is on there and they're peddled certain drugs by the doctors seems like a vicious cycle is there any way to protect ourselves from becoming american addicts it's all about people educating themselves because you can't rely on television ads and even your doctor often enough to tell you exactly what to do and i'll get i'm not bashing the doctors sometimes doctors get a lot of their information from the pharmaceutical companies they are in twined in our medical schools and i was one of them i believe in a conventional medical approach until about nine or ten years ago when i saw that people simply weren't getting better and i had m

sentiment in big pharma, in terms of what areas they are interested in investing in.nk a number of companies look forward to predicting whether they can go public in the coming year and what rockets sentiment will be. >> so you try to walk around and find a let the -- find all of the executives run big pharma, find out how much are they buying cancer, cholesterol drugs? what are the details? >> specifically -- we know the areas they are interested in. but these pipelines -- >> how do these pipelines for drugs work? >> sure. these drugs have to go through multiple stages of the clinical trial process. it can take as little as five years -- >> five years? >> five years is very quick. typically it is 10 to 15 years. >> you are getting a lot of press. >> so, what happens with the pharmaceutical industry, you if you have a lot of enthusiasm about something in your pipeline, it will be six to seven years long and then you have something fail. there will be a gap. everything that is coming to the industry has improved the speed and the visibility -- >> gives the example you

pdl pharma, it's not biogen, regeneron, celgene, gilead. it's a nice spec.e when i recommended. i'm not keen on tobacco. at&t and verizon. we can't have both of these. that's not going to work. i know you want some yield and you feel like yield should be the thing here. i'm going to send you to another stock that was downgraded today. clorox. and that, ladies and gentlemen, is another round of am i diversified. >>> after the close one of my bankable 21 ceos from macy's reported a number that was really good and sent the stock up after hours. i like macy's. just for you right here on "mad money." i'm jim cramer and i will see you tomorrow! [ helicopter blades whirring ] [ sea gulls squawking ] [ indistinct shouting ]

this is a company being challenged by the four horseman of the pharma apocalypse.id you see celgene today? a nice run last year. i think it will tread water in 2014. i see it as being hard pressed to go above $34. look, at the end of the day, i just see pfizer as one of the bigger blahs of the dow, you hear the dogs of the dow. i don't know, maybe it has something up its sleeve but i don't think so. number 23 is proctor & gamble. i think people will continue to bail on the slower growing p&g in favor of cyclical stocks like the industrials, like at the end of last year. however, i think they would be wrong to sell. i think the ceo will make some big changes in 2014. i think this is why you must own it. frankly the company is too big and too layered. there's still a lot of heavy lifting to do. this is the time to buy proctor when a lot can be done. hence, i think the stock can run to $95 up from $80.54. but i wouldn't be surprised if it went to $78 first. especially if the stocks splits off the slower growing divisions. then there's travelers. it's a terrific insura

does big pharma impact the doctors in their decision to not offer alternatives to the pill here? >> i think that there is evidence that if you have interactions with pharmaceutical companies, it does impact -- and there's actually pretty good studies based -- that have looked at physician prescribing patterns and interactions with big pharma. i think one of the luxuries i have is i'm in academic medicine, and we have a policy that we don't interact with pharmaceutical companies. so i hope that gives me a better perspective. and i think a lot of these doctors aren't having these conversations with their patients because i have countless patients who come to me and said they have never heard of iud's. so i think there is some impact of that. we know there's an impact of that. and it makes it challenging, you know, to -- to have a completely unbiased view even though we as doctors like to think we have an unbiased view, there has been evidence that shows that they do impact us in some ways. so i think it's important for us to go out and educate our providers too. there is no one siz

look at intercept pharma last week, although to be fair, they gave up 190 points this monday and tuesday a massive speculative gain, take the money and run, steve miller style. which brings me to a small and very controversial $750 million company, galena biopharma, a name i got asked about last week. at the time trading at 6 bucks, gave it my blessing now up to $7.48. 18% gain in a week's time. galena is an oncology play and a new vaccine to prevent the recurrence of breast cancer in people who have already survived the disease. it is in phase three trials but thestreet.com's biotech expert, a company a founded, has been skeptical about the science behind the phase two study. personally, after galena's incredible run, i think it's reasonable to take a little off the table. bulls make money, bears make money, hogs get slaughtered. i think it needs more research. we're going straight to the source. the president and ceo of galena. welcome to "mad money". >> great to be here. >> we have some recent news. you announced this week a partnership for neuvax in india, the commercial rights to ne

i am nothing but a flesh sack propped up by the wonders of big pharma! (laughter) for starters i take steroids just for the testicle shrinking. (laughter) left unchecked, my balls would keep growing like beaver teeth. (laughter) and obviously i've got to popped a ral to stay focused when people who aren't me are talking. (laughter) i take some ambien because i have trouble sleeping during the commercial breaks. then i just hit the basics-- centrum, soma, neuroin, the spice, glint, glimmer, jizadrine the wii, powdered rhino horn, the blue, boniva, flint stone's chewables, flint stone's spoz suppositories, front line flea and tick on the back of my neck so i can't lift it off and i've got a nuvaring up in there somewhere. (cheers and applause) not entirely sure where, but i'm walking funny. (laughter) of course, kids, you'll have to experiment to get your own cocktail dialed in. mine took a lot of trial and error-- trial in that i've been on trial for taking bath salts and then error of attempting to eat someone's face. once again, my apologies to doris ke

. >> intercept pharma, jumping again nearly after quadrupling yesterday. the stock getting a big boost from upbeat study for a drug used to treat liver disease. now speculation the company could be a takeover target. murph? >> baby, $70 two days ago, $450 today. someone going to take them out after that type of run? i don't know. one of the analysts came out, raised their target from 80 to 840. this drug better be really, really good to support this kind of a move. i don't know how someone would come in and buy them out after this type of move. >> there's some big money possibly making some big money in this move over the last couple of days. scc capital, one of the bigger holders. there you go. orbimed, number four, $600,000 shares. this is the end of september according to filings. but take a look at that list right there big hedge funds in this name. and likely making some big money if they're still in there because of this move we've seen. >>> coming up on the half, retail stocks are coming up today. sears and target are in the red, is joe still short

s regulatory construct. >> reporter: john murphy is a staff lawyer at pharma, the drug makers' trade group and one of the plaintiffs in the suit. he says federal law gives the food and drug administration the authority to regulate drug imports, and that authority's illegally undercut by the maine law. >> effectively, it permits patients to go onto the internet, which is completely unregulated, and bring prescription drugs into the united states outside of even the f.d.a.'s large federal preview. it's very concerning. >> reporter: like maine pharmacist amelia arnold, who's one of the lead plaintiffs in the suit, murphy says stopping mail-order imports is all about safety. they say most drugs have cheaper generic equivalents, so there's no need to take a chance on foreign pharmaceuticals. murphy says that in 2003, the f.d.a. warned canarx that it was "putting the health of the american public at risk" after the company mailed an order of insulin, a perishable drug that has to be refrigerated. canarx says as soon as that happened, it stopped offering perishable drugs and that it has saf

the country's second largest pharma company is enjoying a bump after filing an application seeking approval for a new advanced melanoma drug. the application came earlier than investors expected. merck's stock touched its 52- week high of $53.44 and closed the day up nearly six and a half percent.late last year the company said it would cut nearly 9-thousand employees. jumpin' juniper. shares of the networking equipment maker hopped more than 7% to $25 dollars monday on word activist hedge fund "elliott management corp" has a plan to raise the company's stock value. the hedge fund is said to have acquired 6.2% of juniper's stock.the fund thinks shares could be worth up to $40 dollars, if juniper increases buybacks, pays a dividend, cuts expenses and streamlines operations. expansion is on the menu for dunkin donuts.the coffee-and- doughnuts chain plans to open more than four hundred new shops in the u-s.380 of the locations will be in new markets in the west including california, colorado and texas.four hundred new shops in the u-s.380 of the locations will be in new markets in the west inc

bit excessive part of that was shared with with with big pharma so the answer is it's always going to be a mixed bag and the way you have to deal with it is to focus on how effectively these programs are run and how. how focused the benefits are on the population that really deserves to have them a really nice example of the. proposals to privatized social security. social security is run the basic retirement benefit in the extremely efficient way by several civil servants who were not very numerous not that highly paid to do a little an excellent job with the basic information management that's required if you put that in their heads if you put the funding of the management of the funds in private hands you would be paid waltz sunbed address and all kinds of people whose and couple levels are much much higher and you would be basically move subtracting from the pool of benefits that would be available to the two. now we have to take a very very quick break but more when we return with dr james golf and then in today's big deal i did harrison and i take on the matter of reckless and g

looking for ways to keep people secure they're selling the access to marketing corporations and big pharma and big agra big consumer products companies who then spy on you in ways to help them sell you stuff more trance fact foods more junk food more junk credit everything to make you on healthy more drugs everything that makes you lazy obese and stupid i.e. american that's what they're in it for and they're succeeded because you've got a jobless mass of obese trog go buy it while going around in their little try cycles at a wal-mart looking for new ways to help plumb the nether regions of their intestines because it's all clogged up thanks to bill gates of the twenty four seven surveillance apparatus which is meant to keep people all the way that they are just look at the average of wal-mart shopper and throw up. as the saying goes there's no place like home but for some there is no country they can call by that name hundreds of thousands of people in latvia have so-called alien passports even though they've never lived anywhere else and naturalization test intended for immigrants is the

dispel concerns about security as well as to discuss some of the challenges of hosting the band under pharma has more now from this year's end impacts. these games are the most expensive million pick history in five times the original price tag but mr putin did stress that over the last five years so cheap was the biggest building site in the world all the venues had to be built from scratch and with huge infrastructural development in terms of roads and rail links and he said because of that it was expected things would go over budget but he said where overspend has not been justified action has been taken and people have actually lost their jobs including a russian olympic committee member who was in charge of the ski jump facility which went six and a half times over budget and he was fired however mr putin did say that there was no corruption among government officials about the evidence was presented it would be investigated russia's law against gay propaganda to mine is rose a lot of calls to boycott the olympics from abroad so this issue was also mentioned it was and again he stressed

bit excessive part of it was shared with with with big pharma so the answer is it's always going to be a mixed bag and the way you have to deal with it is to focus on how effectively these programs are run and how. how focused the benefits are on the population that really deserves to have them a really nice example of this is proposals to privatized social security. social security is run the basic retirement benefit in the extreme really efficient way by federal civil servants who are not very numerous and not that highly paid and who do you know an excellent job with the basic information management that's. if you put that in the hands if you put the funding of that the management of the funds in private hands you would be paid waltz sunbed address and all kinds of people whose and cup levels are much much higher and you would be basically move subtracting from the pool of benefits that would be available to the. now we have to take a very very quick break but more when we return with dr james gulliver that in today's big deal i did harrison and i take on the matter of reckless of g

looking for ways to keep people secure they're selling the access to marketing corporations and big pharma and big agra big consumer products companies who then spy on you in ways to help them sell you stuff more transparent foods more junk food more junk credit everything to make you on healthy more drugs everything that makes you lazy obese and stupid i.e. american that's what they're in it for and they're succeeded because you've got a jobless mass of obese trog oh by the wobbling around of their little try cycles at a wal-mart looking for new ways to help plumb the nether regions of their intestines because it's all clogged up thanks to bill gates of the twenty four seven surveillance apparatus which is meant to keep people away the way that they are just look at the average wal-mart shopper and throw up. brit now in the united states are reportedly threatening to cut support for the syrian opposition unless it agrees to peace talks next week but the syrian national coalition insists that with al qaida rebels on the one hand and assad's regime on the other there's no one else for the w

bit excessive part of it was shared with with with big pharma so the answer is it's always going to be a mixed bag and the way you have to deal with it is to focus on how effectively these programs are run and how. how focused the benefits are on the population that really deserves to have them or. a really nice example of this is proposals to privatized social security. social security is run the basic retirement benefit in the extremely efficient way by federal civil servants who were not very numerous not that highly paid to do a little an excellent job with the basic information management that's required if you put that in their heads if you put the funding of the management of the funds in private hands you would be paid off bad address of all kinds of people whose and couple levels are much much higher and you would be the basically move subtracting from the pool of benefits that would be available to the two. now we have to take a very very quick break but more when we return with dr james then in today's big deal i did harrison and i take on the matter of reckless and governme

. >> when we come back, why is it so hard for big pharma to develop new drugs?at is next on "market makers." stay with us. ♪ >> you are watching "market makers" here in the swiss alps. we're at the world economic forum. steve schwarzman, the ceo of -- thank youd now for spending some time with us. his is not a bad place. do you feel better about the prospect for 2014 then 2013? >> absolutely. last year, we were dealing with the comparison. we have the patent put behind us. we have a pretty robust headline. we have one of the top five pipelines in interest-rate today. >> talk to us about specifically, people tend to focus on individual drugs. they get excited. certain drugs have a lot of promising given markets. there was a drug that you hoped to use to gain a fair amount of share. the multiple sclerosis business. it was rejected. how much of a letdown was that? >> it was not a total surprise. actually created a contingent value and recognized that it would not be an easy thing to bring along to the market. this is a drug that has been developed for quite some ti

looking for ways to keep people secure they're selling the access to marketing corporations and big pharma and big agra and big consumer products companies who then spy on you in ways to help them sell you stuff more trans fat foods more junk food more junk credit everything to make you on healthy more drugs everything that makes you lazy obese and stupid i.e. american that's what they're in it for and they're succeeded because you've got a jobless mass of obese trauco bites while going around in their little try cycles and wal-mart looking for new ways to help plumb the nether regions of their intestines because it's all clogged up thanks to bill gates of the twenty four seven surveillance apparatus which is meant to keep people all the way that they are just look at the average of wal-mart shopper and some are up. well you mentioned selling stuff and of course this comes to this headline here yahoo malware turned european computers into bitcoin slaves search firm remains silent on how its ad servers infected windows p.c.'s of visitors to home page so windows p.c.'s are the ones targeted